Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-480848 dose-ranging study in stable coronary heart disease or CHD-risk equivalent
2005-003590-24Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darapladib in coronary arteriosclerosis and atherosclerotic disease (4 arms), sponsored by GSK. Primary endpoint: Sustained inhibition of plasma Lp-PLA2 activity. Started Oct 2005; status: terminated.
02
Drugs
darapladib
03
Conditions
coronary arteriosclerosisatherosclerotic disease
Beyond the preview
Go deeper on 2005-003590-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003590-24.